GO
Loading...

3 deals in 2 weeks Cramer would ‘buy, buy, buy’

Monday, 15 Jul 2013 | 6:14 PM ET
3 IPOs you need to own
Monday, 15 Jul 2013 | 6:15 PM ET
Mad Money host Jim Cramer helps investors prepare their trade on 3 upcoming IPOs: RetailMeNot, OncoMed Pharmaceuticals and Agios.

(Click for video linked to searchable transcript of this Mad Money segment)

Looks like the next 10 business days are going to be rather busy.

Cramer thinks there are three IPOs coming that you should get in on. However, you'll need to be nimble.

"The first one is an online consumer play that should price this Thursday and start trading on Friday," Cramer said.

The company is called RetailMeNot, the world's number one purveyor of digital coupons with 24 million unique visitors clicking on the site last year. Whenever someone uses a coupon taken from one of their websites, either on the Internet or in an actual store, they collect a commission," he said.

Although the Mad Money host likes the business, in the near-term, he sees this IPO as more of a fast money trade than long-term investment simply because of the recent price action in other IPOs that were similar.

Adam Jeffery | CNBC

"Remember, Groupon rallied 31% in its first day of trading," Cramer said, although it later declined sharply.

Therefore, "I think this may be a case in which you should get in on the deal and then quickly get out. I say, you call your broker and try to get shares as long as it actually prices at $24 or less. Then you need to turn around and sell RetailMeNot into the initial spike right after it comes public. Just take the money and run."

Then, in the weeks and months ahead, Cramer thinks you can again revisit the stock and develop a longer term thesis.

Elsewhere in the market Cramer is also a buyer of OncoMed Pharmaceuticals which prices on Wednesday and then starts trading on Thursday.

"This one is an early stage biotech firm focused on anti-cancer drugs and it reminds me of Epizyme, another cancer fighting biotech that came public at the end of May; it roared 53% in its first day of trading, and hasn't looked back since," Cramer said.

In this case, Cramer expects both an early pop and also long-term gains due to the promise of OncoMed's revolutionary approach to developing cancer treatments.

Looking at the IPO, "The company plans to sell four million shares at a price range of $14 to $16. If you can get in on the OncoMed deal, I say ring the register on some into the first-day pop and then let the rest ride," Cramer said.

Also the Mad Money host is bullish on Agios Pharma IPO.

"Here's a company that's right in my two favorite pharma sweet spots, oncology and orphan drugs that treat a subset of genetic metabolic diseases," Cramer said.

"Agios plans to sell five million shares at $14 to $16 a piece next week, and this is another one where, if you can get a piece of the deal, you should take some profits into the strength I expect on the first day of trading and let the rest ride."

-------------------------------------------------------
Read More from Mad Money with Jim Cramer
Breakout? Telltale chart patterns
Cramer: Two banks that should be bought
UPS calling recovery into question?
-------------------------------------------------------

On a related note, Cramer said that NRG Yield IPO is also worth watching. "It's a spin-off of NRG Energy," Cramer explained. "NRG Yield is going to be their dividend vehicle, the plan is for the company to sport a 6% yield. Because high yield stocks are currently out of favor, I can't bless this IPO right now, but it is absolutely worth watching for the long-term," he said.

Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com

  Price   Change %Change
GROUPON
---
NRG
---

Featured

Contact Mad Money

  • Showtimes

    Monday - Friday 6p ET
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.